New neuroscience company Cerevance launched to tackle brain diseases

Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders, has been launched by Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) and Lightstone Ventures. The company will use a new technology, created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, at the Rockefeller University. Takeda will jumpstart the new company by providing a 25-person neuroscience research team from its Cambridge, UK, site, including industry veteran Mark Carlton, fully equipped laboratory space, and licenses to a portfolio of preclinical and clinical stage drug programs. Cerevance is funded with $36 million that includes a $21.5 million Series A financing investment from Takeda and Lightstone Ventures, with each joining Cerevance’s board of directors. “Seven of the ten leading causes of disability in the world are…

Link to Full Article: New neuroscience company Cerevance launched to tackle brain diseases

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!